Periprocedural anticoagulation during left atrial ablation: interrupted and uninterrupted vitamin K-antagonists or uninterrupted novel anticoagulants

Table 6 Patients with thromboembolic events

	Age	Gender	CHA₂DS₂-VASc	Anticoagulation	Clinic	CT Scan	Other	Diagnosis
Patient 1	65	female	2	DOAC/Rivaroxaban	Temporary paraesthesia of the right leg	No signs of stroke	MRI: herniation LS 4/5	Puncture related paraesthesia OR TIA
Patient 2	52	male	0	DOAC/Rivaroxaban	Visual impairment 24 postprocedural Restitutio after 3 h	No signs of stroke	Duplex: no pathology	TIA
Patient 3	45	male	2	DOAC/Apixaban	Visual impairment	No signs of stroke	Opth: Choroidal nevus	TIA
Patient 4	73	female	3	DOAC/Apixaban	Visual impairment	No signs of stroke	Duplex: no pathology	TIA
Patient 5	52	male	2	Bridging	Visual impairment	No signs of stroke	Duplex: no pathology	TIA
Patient 6	72	female	3	VKA	Visual impairment	No signs of stroke	Duplex: no pathology	TIA
Patient 7	71	male	3	VKA	Hemianopsia	Signs of stroke		Stroke of the posterior cerebral artery
Patient 8	47	male	0	VKA	Aphasia	Signs of stroke		Stroke right frontal operculum

Legend: Bridging interrupted vitamin-K-antagonist, DOAC uninterrupted non-vitamin-K anticoagulants, VKA uninterrupted vitamin-K-antagonist

ISSN: 1471-2261